anti-B7-H3 antibody-based ADCs (Helixon)

B7-H3/CD3靶向抗体偶联药物 (华深智药)

Report date: 2026/05/15 20:01:45

Base Information

Drug Nameanti-B7-H3 antibody-based ADCs (Helixon)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-CD276Anti-CD3

TargetsCD276 antigenT cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHelixon Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHelixon Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A